Extension Study Evaluating The Safety And Tolerability of AMX0035

PHASE3CompletedINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

December 29, 2022

Primary Completion Date

October 16, 2024

Study Completion Date

October 30, 2024

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

AMX0035

Combination of 3 g phenylbutyrate and 1 g taurursodiol

Trial Locations (46)

Unknown

University Hospitals Leuven, Leuven

Hospices Civils de Lyon Hôpital Neurologique Pierre Wertheimer Cellule Mutualisée de Recherche Clinique (CMRC), Bron

Hopital Gabriel Montpied Service de Neurologie, Clermont-Ferrand

CHRU de Lille - Hôpital Roger Salengro, Lille

CHU de Limoges - Hôpital Dupuytren, Limoges

Hôpitaux Universitaires de Marseille Timone, Marseille

CHU de Montpellier, Montpellier

Gui de Chauliac, Montpellier

CHU Nice, Nice

Hôpital de la Salpêtrière, Paris

Le Centre Hospitalier Régional Universitaire de Tours, Tours

Uniklinikum Dresden, Dresden

Hannover Medical School, Hanover

Jena University Hospital, Jena

Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim

University Medical Center Rostock, Rostock

Ulm University Medical Centre, Ulm

Trinity College Dublin/Beaumont Hospital, Dublin

Università degli Studi di Bari Aldo Moro, Bari

Centro Clinico NEMO, Milan

IRCCS - Ospedale San Raffaele, Milan

University of Milan Medical School, Milan

IRCCS - Istituto Auxologico italiano, Milan

Azienda Ospedaliero Universitaria Di Modena, Modena

Università degli Studi della Campania Luigi Vanvitelli, Napoli

University of Padua, Padua

Università degli Studi di Bari Aldo Moro, Tricase

University of Torino, Turin

University Medical Center Utrecht, Utrecht

Centrum Medyczne Linden, Krakow

City Clinic Warsaw, Warsaw

Centro Hospitalar Universitário Lisboa-Norte, Lisbon

Hospital del Mar, Barcelona

Hospital Universitari de Bellvitge-IDIBELL, Barcelona

Hospital Universitario de Basurto, Bilbao

Hospital San Rafael, Madrid

Biodonostia Health Research Institute; Hospital Universitario Donostia, San Sebastián

Hospital Universitario y Politécnico La Fe, Valencia

Karolinska Institutet, Stockholm

Umeå University Hospital, Umeå

The Walton Centre NHS Trust, Liverpool

King's College London, London

UCL Queen Square Institute of Neurology, London

University of Plymouth, Plymouth

Salford Royal Hospital Barnes Clinical Research Team, Salford

Sheffield Institute for Translational Neuroscience (SITraN), Sheffield

Sponsors
All Listed Sponsors
lead

Amylyx Pharmaceuticals Inc.

INDUSTRY

NCT05619783 - Extension Study Evaluating The Safety And Tolerability of AMX0035 | Biotech Hunter | Biotech Hunter